Acute Pulmonary Exacerbation Phenotypes in Patients with Cystic Fibrosis.
Suzanne C CarterAlessandro N FranciosiKate M O'SheaOrla M O'CarrollAshutosh SharmaAoife BellBrian KeoganPaul O'ReillySuzie CoughlanSheonagh M LawRobert D GrayKatherine B HisertPradeep K SinghGordon CookeBrenda GroganCillian F De GascunCharles G GallagherTrevor T NicholsonBradley S QuonEdward F McKonePublished in: Annals of the American Thoracic Society (2022)
Rationale: The etiology of cystic fibrosis (CF) pulmonary exacerbations (PEx) is likely multifactorial with viral, bacterial, and non-infectious pathways contributing. Objectives: To determine whether viral infection status and CRP (C-reactive protein) can classify subphenotypes of PEx that differ in outcomes and biomarker profiles. Methods: Patients were recruited at time of admission for a PEx. Nasal swabs and sputum samples were collected and processed using the respiratory panel of the FilmArray multiplex polymerase chain reaction (PCR). Serum and plasma biomarkers were measured. PEx were classified using serum CRP and viral PCR: " pauci-inflammatory " if CRP < 5 mg/L, " non-viral with systemic inflammation " if CRP ⩾ 5 mg/L and no viral infection detected by PCR and " viral with systemic inflammation " if CRP ⩾ 5 mg/L and viral infection detected by PCR. Results: Discovery cohort ( n = 59) subphenotype frequencies were 1 ) pauci-inflammatory (37%); 2 ) non-viral with systemic inflammation (41%); and 3 ) viral with systemic inflammation (22%). Immunoglobulin G, immunoglobulin M, interleukin-10, interleukin-13, serum calprotectin, and CRP levels differed across phenotypes. Reduction from baseline in forced expiratory volume in 1 second as percent predicted (FEV 1 pp) at onset of exacerbation differed between non-viral with systemic inflammation and viral with systemic inflammation (-6.73 ± 1.78 vs. -13.5 ± 2.32%; P = 0.025). Non-viral with systemic inflammation PEx had a trend toward longer duration of intravenous antibiotics versus pauci-inflammation (18.1 ± 1.17 vs. 14.8 ± 1.19 days, P = 0.057). There were no differences in percent with lung function recovery to <10% of baseline FEV 1 pp. Similar results were seen in local and external validation cohorts comparing a pauci-inflammatory to viral/non-viral inflammatory exacerbation phenotypes. Conclusions: Subphenotypes of CF PEx exist with differences in biomarker profile, clinical presentation, and outcomes.
Keyphrases
- cystic fibrosis
- sars cov
- lung function
- chronic obstructive pulmonary disease
- oxidative stress
- pseudomonas aeruginosa
- emergency department
- end stage renal disease
- chronic kidney disease
- type diabetes
- clinical trial
- intensive care unit
- newly diagnosed
- mycobacterium tuberculosis
- small molecule
- high dose
- air pollution
- peritoneal dialysis
- rheumatoid arthritis
- adipose tissue
- high throughput
- systemic lupus erythematosus
- mechanical ventilation
- real time pcr
- patient reported